Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration
This study has been completed.
Study NCT00061594   Information provided by Genentech
First Received: May 29, 2003   Last Updated: September 1, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Macular Degeneration
More general conditions related to this trial
Eye Diseases
Retinal Degeneration
Retinal Diseases
Interventions listed in this trial
rhuFab V2 (ranibizumab)
Additional drug interventions recognized in this trial
Verteporfin
More general drug interventions related to this trial
Dermatologic Agents
Pharmacologic Actions
Photosensitizing Agents
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services